Marika Sherman

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

James N. Kochenderfer, Robert Somerville, Tangying Lu et al. · Journal of Clinical Oncology · 2017 · 561 citations

Medicine, Hematology, Immunology +17

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Frederick L. Locke, John M. Rossi, Sattva S. Neelapu et al. · Blood Advances · 2020 · 455 citations · Full text

Medicine, Immunology, Oncology +17

Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett et al. · Blood · 2017 · 181 citations

Medicine, Oncology, Pharmacology +14

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Max S. Topp, Tom van Meerten, Roch Houot et al. · British Journal of Haematology · 2021 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing

Sandra L. Ross, Marika Sherman, Patricia McElroy et al. · PLoS ONE · 2017 · 112 citations · Full text

Life Sciences, Immunology, Oncology +17